Analysts Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $9.95

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) have been given an average recommendation of “Moderate Buy” by the ten analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $9.29.

Several research analysts recently weighed in on the company. Citizens Jmp raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Friday, March 14th. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 14th. HC Wainwright dropped their target price on Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th.

Insider Buying and Selling

In related news, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.66. Following the completion of the transaction, the insider now owns 250,713 shares of the company’s stock, valued at $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the sale, the chief executive officer now directly owns 5,276,569 shares in the company, valued at $10,342,075.24. The trade was a 0.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 104,866 shares of company stock valued at $194,461 over the last three months. 24.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Allogene Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Lynx1 Capital Management LP increased its holdings in Allogene Therapeutics by 75.3% during the 4th quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company’s stock valued at $23,163,000 after purchasing an additional 4,672,349 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Allogene Therapeutics by 30.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company’s stock valued at $7,586,000 after buying an additional 831,146 shares in the last quarter. Foresite Capital Management VI LLC acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at $7,345,000. Geode Capital Management LLC raised its holdings in shares of Allogene Therapeutics by 14.4% in the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after buying an additional 407,070 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its position in Allogene Therapeutics by 12.1% during the 4th quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company’s stock worth $5,756,000 after buying an additional 291,800 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Stock Down 3.6 %

ALLO stock opened at $1.63 on Friday. The company has a 50-day simple moving average of $1.89 and a 200 day simple moving average of $2.29. The company has a market capitalization of $354.14 million, a P/E ratio of -1.04 and a beta of 1.02. Allogene Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $4.63.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06. Equities analysts anticipate that Allogene Therapeutics will post -1.28 EPS for the current year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).